

Morning Wrap

Today's Newsflow

Select headline to navigate to article

Kerry Group Significant valuation disconnect given robust delivery in tough end-markets

IAG CFO transition

Equity Research

09 Jan 2026

08:57

Upcoming Events

Company Events

| | |
|--------|---|
| 13-Jan | Grafton Group; Q425 Trading Update Persimmon; Q425 Trading Update Trustpilot Group; Q425 Trading Update Whitbread; Q326 Trading Update |
| 14-Jan | Frontier Developments; Q226 Results Vistry Group; Q425 Trading Update |
| 15-Jan | Fuller, Smith & Turner; Q326 Trading Update Glenveagh Properties; Q425 Trading Update Taylor Wimpey; Q425 Trading Update |

Economic Events

Ireland

| | |
|--------|--|
| 09-Jan | Industrial Production Live Register M/M |
| 13-Jan | Retail Sales |
| 15-Jan | CPI Trade Balance |

United Kingdom

| | |
|--------|---|
| 12-Jan | S&P Permanent Job Placements |
| 15-Jan | Manufacturing Production Trade Balance Construction Output GDP |

Goodbody Capital Markets

Equity Research +353 1 6419221

Equity Sales +353 1 6670222

Bloomberg DS GDS<GO>

Kerry Group Significant valuation disconnect given robust delivery in tough end-markets

Kerry reports FY25 results in late February where constant FX EPS guidance of +7-11% should be well underpinned by solid volumes and strong margin delivery. Despite a continued subdued F&B backdrop in key markets (US, China, Europe), we expect 2026 to be another resilient year with solid volumes and further strong margin growth to drive robust EPS delivery. For FY25, our EPS estimates are broadly unchanged (€4.87, +9% yoy on +3.0% volumes) though we nudge FY26 EPS lower (-1% to €5.35, +10% yoy) on more prudent volumes (+3.4% vs. +3.8% prior), albeit still tracking >300bps ahead of the wider F&B market.

We expect +3.0% organic volumes in Q4'25 (Americas +2.8%, Europe +0.1%, APMEA +5.9%) reflecting solid progress in private label, foodservice and overall renovation momentum (health & wellness, fortification, cost reduction), offset by a slightly tougher comp (+4.1%, FY24 +3.4%). For 2026, we expect some modest incremental volume improvement, not least on easier comps in China (Americas +3.2%, Europe +0.8%, APMEA +6.0%). Following 80bp EBITDA margin improvement in 2025 (to 17.9%), we expect +60bp gains in 2026 as Accelerate 2.0 benefits (capacity rationalisation, IT transformation) start to come through.

While sentiment towards Staples has been weak in recent months, Kerry shares are now -30% from Mar-25 highs, despite just modest volume downgrades (initial view c.+3.5% for 2025) and unchanged (& still robust) EPS growth/guidance. KYG now trades on just 13.8x 2026 P/E and 10.4x EV/EBITDA. This is the lowest absolute in over 10 years and also near relative lows to peers & consumer staples.

[Home...](#)

IAG CFO transition

IAG has announced that Nicholas Cadbury has decided to step down as CFO of the Group and he will leave the Group effective from June 2026. José Antonio Barrionuevo has been appointed CFO from June 2026. Mr Barrionuevo is currently Chief Financial and Transformation Officer at British Airways having held previous roles in the Group including seven years as the CFO of Iberia. In our opinion, given the balance sheet transformation, increase in earnings and increase in returns over the last few years, investors held a positive view on Mr Cadbury so there may be some disappointment that he has decided to step down. However, an internal candidate who has been CFO at the two largest airlines in the Group with a near six-month lead time should result in a relatively seamless transition.

Recommendation: Buy
Closing Price: €73.50

Patrick Higgins
+353-1-641 0403
patrick.m.higgins@goodbody.ie

Recommendation: Buy
Closing Price: £4.32

Dudley Shanley
+353-1-641 9174
dudley.c.shanley@goodbody.ie

[Home...](#)

Issuer & Analyst Disclosure

Analyst Certification

The named Research Analyst certifies that: (1) All of the views expressed in this research report accurately reflect my personal views about any and all of the subject securities and issuers. (2) No part of my remuneration was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this report.

Regulatory Information

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a wholly owned subsidiary of Allied Irish Banks, p.l.c. This publication has been approved by Goodbody. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

Conflicts of Interest

Goodbody has procedures and policies in place to identify and manage any potential conflicts of interest that arise in connection with its research business. Goodbody analysts and other staff who are involved in the preparation and dissemination of research operate and have a management reporting line that is independent to its business. Information barriers are in place between the Corporate Finance arm and the Research arm to ensure that any confidential and or price sensitive information is handled in an appropriate manner.

Our Investment Research Conflicts of Interest Policy is available at [Conflicts of Interest](#)

Investors should be aware, that, where appropriate, research may be disclosed to the issuer(s) in advance of publication, in order to correct factual inaccuracies only and not to materially amend the research in any way. Goodbody is satisfied that it has operational procedures in place, which ensure that such disclosures will not compromise the report's objectivity.

The list of companies for which Goodbody acts as market maker and on which it provides research, is available at [Regulatory Disclosures](#)

Other disclosures

A description of this company is available at [Company Descriptions](#)

All prices used in this report are as at close of business of the 7th of January 2026.

The time of publication of the report is Irish Standard Time (UTC +1), which accounts for transitions between IST and GMT (i.e. daylight saving time).

A summary of our standard valuation methods are available at [Valuation Methodologies](#)

A summary of share price recommendations and whether material investment banking services have been provided to these companies is available at [Regulatory Disclosures](#)

Other important disclosures are available at [Regulatory Disclosures](#)

Goodbody updates its recommendations on a regular basis. A breakdown of all recommendations provided by Goodbody is available at [Regulatory Disclosures](#) Where Goodbody has provided investment banking services to an issuer, details of the proportion of buys, holds and sells attributed to that issuer will also be included. This is updated on a quarterly basis.

Recommendation Definitions

Goodbody uses the terms "Buy", "Sell" and "Hold. The term "Buy" means that the analyst expects the security to appreciate in excess of 10% over a twelve month period. The term "Sell" means that the security is expected to decline in excess of 10% over the next twelve months. The term "Hold" means that the analyst expects the security to neither appreciate more than 10%, or depreciate more than 10% over the next twelve months.

On 26th November, 2012, the terms "Add" and "Reduce" were removed from the Recommendation Definitions and both were replaced with the "Hold" recommendation. Any Previous Recommendation that refers to either an "Add" means that the analyst expected the security to appreciate by up to 15% over a twelve month period. Any Previous Recommendation to "Reduce" means that the analyst expected the security to decline by up to 15% over the next twelve months.

In the event that a stock is delisted the firm will automatically cease coverage. If however the firm ceases to cover a stock for any other reason the firm will disclose this fact.

Distribution of Research to US Investors

Goodbody Stockbrokers UC acts as a market maker and distributes investment research to US major institutional investors and all transactions by US persons involving securities of companies discussed in reports distributed by Goodbody Stockbrokers UC are to be effected via Goodbody Securities, Inc. ('GSI'), a member firm of FINRA and SIPC. GSI is an affiliate of Goodbody Stockbrokers UC and does not act as a market-maker or maintain any positions in any security.

Details of all such positions that are the subject of the research are disclosed in the research reports and at www.goodbody.ie/legal-and-regulatory-disclosures/. This information was current as of the last business day of the month preceding the date of the report.

An affiliate of GSI may have acted, in the past 12 months, as lead manager/co-lead manager of a publicly disclosed offer of the securities in this company. Investors should be aware that an affiliate of GSI may have provided investment banking or non-investment-banking services to, and received compensation from this company in the past 12 months or may provide such services in the next three months. The term investment banking services includes acting as broker as well as the provision of corporate finance services, such as underwriting and managing or advising on a public offer.

Estimates/forecasts developed by Goodbody Research may not be met. Additional information is available, upon request to Goodbody Research, about the bases and assumptions behind the conclusions reached in Research reports.

Disclaimer

While all reasonable care has been taken in the production and dissemination of this report it is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you.

Private customers having access, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested. Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities.

All material presented in this report, unless specifically indicated otherwise is copyright to Goodbody. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody.